Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07811869Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Primary completion
- Feb 2029
- Countries
- 2
01
Overview
A Phase 3 trial of remibrutinib in chronic pruritus of unknown origin (CPUO), sponsored by Novartis. Started Oct 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic pruritus of unknown origin (CPUO)
Beyond the preview
Go deeper on NCT07811869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811869.